NCT00536952View on ClinicalTrials.gov

Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2016

Conditions
Head and Neck Cancer
Interventions
DRUG

Pulmozyme

Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer

DRUG

Placebo

Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer

RADIATION

Radiation Therapy

5 days per week for 4 weeks

Trial Locations (1)

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Northwestern University

OTHER